Live pharma industry news from FDA, Fierce Pharma, and BioPharma Dive. Updated continuously with the latest drug pricing, regulatory, and market developments.
Original data-driven analysis from the RxFinder team.
HRSA’s 2026 oversight of 340B program integrity in mobile health units now targets gaps in eligibility, dispensing records, and contract pharmacy tie-ins.
Dialysis centers face new HRSA 2026 audit priorities on 340B patient eligibility, inventory control, and contract pharmacy oversight.
Behavioral health hospitals face new HRSA 2026 audit priorities around patient definition, documentation, and contract pharmacy oversight.
HRSA’s 2026 audits are zeroing in on eligibility, prescription origination, and contract pharmacy matching at women’s health clinics.
How rural health clinics can align with HRSA’s 2026 audit focus on provider eligibility, dispensing records, and contract pharmacy oversight.
HRSA’s 2026 contract pharmacy oversight focuses on restocking delays tied to manufacturer shipping pauses and ESP data mismatches.
HRSA’s 2026 340B audits are targeting clinic-dispense programs. Here’s how pharmacy-owned clinics can prove prescription origin and link inventory cleanly.
HRSA’s 2026 340B audits are hitting outpatient mental health clinics harder on eligibility proof and contract pharmacy claim checks.
HRSA’s 2026 enforcement focus on telehealth-dispensed 340B prescriptions is exposing diversion risks for FQHC and hospital covered entities.
HRSA audits in 2026 are targeting outpatient surgery centers in 340B. Here’s how to track inventory, handle contract pharmacies, and stay compliant.
Live headlines from leading pharma and regulatory news sources. Links open original articles.
The Food and Drug Administration is advising consumers not to purchase or use X10 Natural Enhancement Supplement, a product promoted for sexual enhancement on various websites, including naturefuel.us
This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.
Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.
Learn about the warnings for sexual enhancement and energy products that contain hidden drugs and other hidden ingredients.
The Food and Drug Administration is advising consumers not to purchase or use Big Dick Energy!, a product promoted and sold for male sexual enhancement on various websites and possibly in some retail
Generic Drug Facilities, Sites and Organization Lists
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
The Food and Drug Administration is advising consumers not to purchase or use Erectus Plus, a product promoted and sold for male sexual enhancement on various websites, including ebay.com, and possibl
Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
A twice-spurned therapy that's been seen as one of the FDA's more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
As leadership changes create more instability at the FDA, here's what one former agency official thinks it will take to keep speedier drug approvals on track.
Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.
The findings supporting bepirovirsen were deemed a "historic moment" by physicians and validate a drug that has "clear blockbuster potential," according to one analyst.
The agreement includes Lilly's new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
Seeking a share of the first-line diffuse B-cell lymphoma market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-CHOP regimen and
After winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sen
With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insulin powder.
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for
News headlines are sourced from third-party RSS feeds and are the property of their respective publishers. RxFinder does not endorse or verify third-party content. Links open original source articles.